The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer
Published version of a preprint
Abstract
Purpose: KRAS is among the most commonly mutated oncogene in cancer including non–small cell lung cancer (NSCLC). In early clinical trials, inhibitors targeting G12C-mutant KRAS have achieved responses in some patients with NSCLC. Possible intrinsic and acquired resistance mechanisms to KRAS G12C inhibitors are not fully elucidated and will likely become important to identify. Experimental Design: To identify potential resistance mechanisms, we defined the sensitivity of a panel of KRAS G12C–mutant lung cancer cell lines to a KRAS G12C inhibitor, AMG510. Gene set enrichment analyses were performed to identify pathways related to the sensitivity, which was further confirmed biochemically. In addition, we created two cell lines that acquired resistance to AMG510 and the underlying resistance mechanisms were analyzed. Results: KRAS expression and activation were associated with sensitivity to KRAS G12C inhibitor. Induction of epithelial-to-mesenchymal transition (EMT) led to both intrinsic and acquired resistance to KRAS G12C inhibition. In these EMT-induced cells, PI3K remained activated in the presence of KRAS G12C inhibitor and was dominantly regulated by the IGFR–IRS1 pathway. We found SHP2 plays a minimal role in the activation of the PI3K pathway in contrast to its critical role in the activation of the MAPK pathway. The combination of KRAS G12C inhibitor, PI3K inhibitor, and SHP2 inhibitor resulted in tumor regressions in mouse models of acquired resistance to AMG510. Conclusions: Our findings suggest that EMT is a cause of both intrinsic and acquired resistance by activating the PI3K pathway in the presence of KRAS G12C inhibitor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While previous studies have characterized acquired resistance to KRASG12C inhibition and identified causal mutations and non-genetic mechanisms including RTK activation and epithelial-to-mesenchymal transition11–14,35, the mechanisms underlying differential sensitivity to KRASG12C inhibition are less well understood.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [35]
In the citing paper
“One major route leading to such recovery of RAS activity is the activation of RTKs through either genetic (e.g., gene amplification or fusion) or non-genetic mechanisms.2,4,5,6,7,8,22,23,24,25”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [22]
In the citing paper
“Previously, inhibition of multiple RTKs through adaptors like SOS and SHP2, which function downstream of RTKs to promote RAS activation, has shown promise in preclinical studies aimed at mitigating acquired resistance to KRAS inhibition.7,22,26”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [22]
In the citing paper
“RTKs were also implicated in resistance to KRAS G12C inhibition associated with epithelial-mesenchymal transition (EMT) [77, 78].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [77]
In the citing paper
“Mesenchymal-like KRAS G12C NSCLC cells treated with sotorasib showed induction of RTKs, including FGFR1 and ERBB3, and stable PI3K signaling maintained by the insulin-like growth factor (IGFR)/insulin receptor substrate-1 (IRS1) axis [77].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [77]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Whereas the relationship between KRAS gene amplification and sensitivity to another KRAS inhibitor, ARS-1620, was not clear in a previous report (17), the potency of AMG510 is approximately 10-fold as compared with ARS1620 in a nucleotide-exchange assay with recombinant GDP-bound KRAS G12C (9).”
BackgroundPhosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954 · cited 1×
“Activated RAS proteins bind directly to an N-terminal RAS-binding domain on p110a, acting synergistically with the input from tyrosine-phosphorylated proteins to optimally activate lipid kinase activity (37, 38).”
BackgroundResistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409 · cited 1×
“While these observed responses in KRAS-mutant patients with NSCLC are encouraging, even in the most successful NSCLC targeted therapy paradigms like EGFR-mutant NSCLC and ALK translocated NSCLC, both adaptive and acquired resistance limit targeted therapy efficacy (13, 14).”
BackgroundEngelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · cited 1×
“Blockade of bothMAPK and PI3K has been proposed as a means to achieve synergistic cell killing and to abrogate adaptive resistance to single-axis targeted therapies in variable cancers including KRASmutant cancers (44).”
BackgroundHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 1×
“Pharmacologic and/or CRISPR Cas9 screening identified several candidates including SHP2 (10, 17, 18, 43).”
BackgroundActivation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130 · cited 3×
“However, even before these molecules were available, it was clear some KRAS-mutant NSCLCs were not markedly sensitive to genetic ablation of mutant KRAS.”
Background
Cited by
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
“https://doi.org/10.1038/s41591-024-02903-0 sotorasib harbor increased activation of EMT programs with parallel activation of the PI3K pathway 63 .”
InfluentialExpanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
“4) and fall into six different classes: i) KRAS mutations in the switch II pocket that block inhibitor binding (secondary mutations in KRAS residues R68, H95, or Y96), ii) activating KRAS mutations (G12D, G12R, G12V, G13D, or Q61H) likely in a trans allele configuration, iii) cis allele conversion of the KRASG12C codo…”
BackgroundKoga, T., Suda, K., Fujino, T., Ohara, S., Hamada, A., Nishino, M., Chiba, M., Shimoji, M., Takemoto, T., Arita, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.015 · Cited by 265
“resistance was reported owing to resynthesis of KRAS that immediately associates with GTP and an epithelialto mesenchymal transition.(24,25)”
Background
Metadata
- Authors
- Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H.
- Affiliations
- Aichi Cancer Center (JP)
- National University of Singapore (SG)
- Venue
- Clinical Cancer Research
- Published
- 2020-11-13
- Volume
- 26
- Issue
- 22
- Pages
- 5962-5973
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3084225156
- Semantic Scholar
- e1804f44a37112a10202fa7a3313a2a6507837e5
- Cited by
- 249
- References
- 47
- Citations by year
- 2026: 45 · 2025: 49 · 2024: 46 · 2023: 38 · 2022: 44 · 2021: 26 · 2020: 1
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- JSPS (15KK0303)
- AMED (19cm0106513h0004)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- epithelial-mesenchymal transition, KRAS G12C, KRAS G12C inhibitors, sotorasib, acquired drug resistance, intrinsic drug resistance, non-small cell lung cancer, PI3K signaling, SHP2, combination therapy
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Mutation, Piperazines, Pyridines, Pyrimidines, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Insulin Receptor Substrate Proteins, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-2077
- The paper
- Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020). Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-2077
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.